Incytevs.United Therapeutics
INCY vs UTHR · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Incyte and United Therapeutics are similar in size by market cap; Incyte trades at the lower P/E (14.2 vs 17.4); year to date, Incyte leads (+14.2% vs +9.3%).
Side by side
| INCY | UTHR | |
|---|---|---|
| Market cap | $22.9B | $22.9B |
| Price | $112.79 | $549.16 |
| Today | +0.0% | +3.1% |
| Return YTD | +14.2% | +9.3% |
| Return 1Y | +32.1% | +18.7% |
| Since June 26, 2026 | −0.8% | +1.2% |
| P/E | 14.2 | 17.4 |
| P/S | 3.9 | 7.2 |
| P/B | 3.6 | 3.6 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
IncyteINCY
Jakafi in myelofibrosis and Opzelura in dermatology anchor a portfolio split between cancer and inflammation.
Full INCY profile →United TherapeuticsUTHR
Pulmonary hypertension accounts for the marketed drugs, Tyvaso, Remodulin and Orenitram among them. A separate programme works on organs for transplant, including xenotransplantation.
Full UTHR profile →More INCY & UTHR comparisons
Other head-to-heads in the Biotech & innovation segment.